About: Treatment of Acute Ischemic Stroke due to Large Vessel Occlusion With COVID-19: Experience From Paris

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment of Acute Ischemic Stroke due to Large Vessel Occlusion With COVID-19: Experience From Paris Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Treatment of Acute Ischemic Stroke due to Large Vessel Occlusion With COVID-19: Experience From Paris
Creator	Blanc, Raphael Ciccio, Gabriele Delvoye, François Desilles, Jean-Philippe Escalard, Simon Hébert, Solène Mazighi, Mikael Maïer, Benjamin Piotin, Michel Redjem, Hocine Smajda, Stanislas
source	Medline; PMC
abstract	BACKGROUND AND PURPOSE: Higher rates of strokes have been observed in patients with coronavirus disease 2019 (COVID-19), but data regarding the outcomes of COVID-19 patients suffering from acute ischemic stroke due to large vessel occlusion (LVO) are lacking. We report our initial experience in the treatment of acute ischemic stroke with LVO in patients with COVID-19. METHODS: All consecutive patients with COVID-19 with acute ischemic stroke due to LVO treated in our institution during the 6 first weeks of the COVID-19 outbreak were included. Baseline clinical and radiological findings, treatment, and short-term outcomes are reported. RESULTS: We identified 10 patients with confirmed COVID-19 treated for an acute ischemic stroke due to LVO. Eight were men, with a median age of 59.5 years. Seven had none or mild symptoms of COVID-19 at stroke onset. Median time from COVID-19 symptoms to stroke onset was 6 days. All patients had brain imaging within 3 hours from symptoms onset. Five patients had multi-territory LVO. Five received intravenous alteplase. All patients had mechanical thrombectomy. Nine patients achieved successful recanalization (mTICI2B-3), none experienced early neurological improvement, 4 had early cerebral reocclusion, and a total of 6 patients (60%) died in the hospital. CONCLUSIONS: Best medical care including early intravenous thrombolysis, and successful and prompt recanalization achieved with mechanical thrombectomy, resulted in poor outcomes in patients with COVID-19. Although our results require further confirmation, a different pharmacological approach (antiplatelet or other) should be investigated to take in account inflammatory and coagulation disorders associated with COVID-19.
has issue date	2020-06-08(xsd:dateTime)
bibo:doi	10.1161/strokeaha.120.030574
bibo:pmid	32466736
has license	no-cc
sha1sum (hex)	f7a41d295dcd66809ff6d3b8ffc783bc74603dab
schema:url	https://doi.org/10.1161/strokeaha.120.030574
resource representing a document's title	Treatment of Acute Ischemic Stroke due to Large Vessel Occlusion With COVID-19: Experience From Paris
has PubMed Central identifier	PMC7282400
has PubMed identifier	32466736
schema:publication	Stroke
resource representing a document's body	covid:f7a41d295dcd66809ff6d3b8ffc783bc74603dab#body_text
is schema:about of	named entity 'Experience' named entity 'Stroke' named entity 'therapeutic dose' named entity 'neurological' named entity 'interquartile range' named entity 'AIS' named entity 'COVID-19' named entity 'COVID-19' named entity 'thromboembolic complications' named entity 'COVID-19' named entity 'Thrombolysis' named entity 'mechanical thrombectomy' named entity 'acute ischemic stroke' named entity 'computed tomography' named entity 'Cerebral Infarction' named entity 'COVID-19' named entity 'cardiovascular' named entity 'Cerebral Infarction' named entity 'vessel occlusion' named entity 'COVID-19' named entity 'COVID-19' named entity 'middle cerebral artery' named entity 'COVID-19' named entity 'COVID-19' named entity 'stroke' named entity 'anonymized data' named entity 'COVID-19' named entity 'National Institutes of Health Stroke Scale' named entity 'AIS' named entity 'procoagulant' named entity 'LVO' named entity 'angiographic' named entity 'neutrophil extracellular traps' named entity 'reperfusion' named entity 'first-pass effect' named entity 'MRI' named entity 'magnetic resonance imaging' named entity 'dual antiplatelet therapy' named entity 'Alberta' named entity 'COVID-19' named entity 'infection' named entity 'Thrombolysis' named entity 'informed consent' named entity 'acute coronary syndrome' named entity 'AIS' named entity 'AIS' named entity 'Computed Tomography' named entity 'AIS' named entity 'risk factor' named entity 'mortality rates' named entity 'LVO' named entity 'NIHSS' named entity 'proximal' named entity 'LVO' named entity 'ethics committee' named entity 'Stroke' named entity 'LVO' named entity 'AIS' named entity 'LVO' named entity 'COVID-19' named entity 'COVID-19' named entity 'LVO' named entity 'coagulation' named entity 'coronavirus disease 2019' named entity 'intravenous thrombolysis' named entity 'modified Rankin Scale' named entity 'LVO' named entity 'Alberta' named entity 'COVID-19' named entity 'AIS' named entity 'stroke'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software